Skip to main content

Advertisement

SpringerLink
Log in

Correlation Analysis of JAK-STAT Pathway Components on Prognosis of Patients with Prostate Cancer

  • Research
  • Published:
Pathology & Oncology Research

Abstract

Janus kinases (JAK)/signal transducers and activator of transcription (STAT) pathway is activated constitutively in prostate cancer (PCa). Despite previous reports implying a role of this pathway in the development of clinical hormone-refractory PCa, the correlation of pathway members with the clinicopathologic features and prognosis of patients with PCa has not been elucidated. To address this problem, pJAK-1Tyr1022/1023 and pSTAT-3Tyr705 were evaluated by immunostaining in needle biopsies of the prostate from 202 PCa patients treated by definitive therapy (105 cases) or hormonal therapy (97 cases). The correlation of two protein expression with the clinicopathologic features and the prognosis of PCa were subsequently assessed. The expression levels of pJAK-1Tyr1022/1023 and pSTAT-3Tyr705 were both positively correlated with Gleason score and clinical stage of patients with PCa. Their expression was also significantly higher in patients with biochemical (prostate-specific antigen, PSA) failure than that in those with no PSA failure (both P < 0.001). In all patients, the recurrence-free survival (RFS) rates were significantly higher in those with low pJAK-1Tyr1022/1023 and pSTAT-3Tyr705 expression than that in those with high expression (both P < 0.001). Moreover, for patients treated by definitive or hormonal therapy, the RFS rates in those with lower pJAK-1Tyr1022/1023 (P < 0.001 and 0.012, respectively) and pSTAT-3Tyr705 expression (P < 0.001 and 0.015, respectively) were significantly higher than in those with higher expression. Cox multivariate analysis showed that the expression levels of pJAK-1Tyr1022/1023 (P = 0.002) and pSTAT-3Tyr705 (P = 0.005) were prognostic factors for PCa in addition to extraprostatic extension (P = 0.026) and Gleason score (P = 0.018). The results of pJAK-1Tyr1022/1023 and pSTAT-3Tyr705 immunostainings in needle-biopsy specimens are prognostic factors for PCa.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Reference

  1. Kehinde EO, Maghrebi MA, Anim JT (2008) The importance of determining the aggressiveness of prostate cancer using serum and tissue molecular markers. Can J Urol 15:3967–74

    PubMed  Google Scholar 

  2. Hochreiter WW (2008) The issue of prostate cancer evaluation in men with elevated prostate-specific antigen and chronic prostatitis. Andrologia 40:130–3

    Article  PubMed  CAS  Google Scholar 

  3. Loeb S, Catalona WJ (2008) What to do with an abnormal PSA test. Oncologist 13:299–305

    Article  PubMed  CAS  Google Scholar 

  4. Bolli R, Dawn B, Xuan YT (2003) Role of the JAK-STAT pathway in protection against myocardial ischemia/reperfusion injury. Trends Cardiovasc Med 13:72–9

    Article  PubMed  CAS  Google Scholar 

  5. Booz GW, Day JN, Baker KM (2002) Interplay between the cardiac renin angiotensin system and JAK-STAT signaling: role in cardiac hypertrophy, ischemia/reperfusion dysfunction, and heart failure. J Mol Cell Cardiol 34:1443–53

    Article  PubMed  CAS  Google Scholar 

  6. Gross ER, Hsu AK, Gross GJ (2006) The JAK/STAT pathway is essential for opioid-induced cardioprotection: JAK2 as a mediator of STAT-3, Akt, and GSK-3β. Am J Physiol Heart Circ Physiol 291:827–34

    Article  Google Scholar 

  7. Kandalam U, Clark MA. Angiotensin II activates JAK2/STAT-3 pathway and induces interleukin-6 production in cultured rat brainstem astrocytes, Regul Pept doi:10.1016/j.regpep.2009.09.001

  8. Darnell JE Jr (1997) STATs and gene regulation. Science 277:1630–5

    Article  PubMed  CAS  Google Scholar 

  9. Levy DE, Darnell JE Jr (2002) Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 36:51–62

    Google Scholar 

  10. Calo V, Migliavacca M, Bazan V (2003) STAT proteins: from normal control of cellular events to tumorigenesis. J Cell Physiol 197:157–68

    Article  PubMed  CAS  Google Scholar 

  11. Barton BE, Karras JG, Murphy TF, Barton A, Huang HF (2004) Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: Direct STAT3 inhibition induces apoptosis in prostate cancer lines. Mol Cancer Ther 3:11–20

    PubMed  CAS  Google Scholar 

  12. Agarwal C, Tyagi A, Kaur M (2007) Silibinin inhibits constitutive activation of Stat3, and causes caspase activation and apoptotic death of human prostate carcinoma DU145 cells. Carcinogenesis 28:1463–70

    Article  PubMed  CAS  Google Scholar 

  13. Tam L, McGlynn LM, Traynor P (2007) Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer. Br J Cancer 97:378–83

    Article  PubMed  CAS  Google Scholar 

  14. Schroder FH, Hermanek P, Denis L (1992) classification of prostate cancer. Prostate Suppl 4:129–38

    Article  PubMed  CAS  Google Scholar 

  15. Gleason DF, Mellinger GT (1974) Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111:58–64

    PubMed  CAS  Google Scholar 

  16. Wang L, Guojun Wu, Lei Yu (2006) Inhibition of CD147 expression reduces tumor cell invasion in human prostate cancer cell line via RNA interference. Cancer Biol Ther 5:608–14

    Article  PubMed  CAS  Google Scholar 

  17. Pulukuri S, Patel J, Estes N (2007) Matrix metalloproteinase-1 (MMP-1) expression and biological signiWcance in the progression of prostate cancer (abstract). In: American Association for Cancer Research Annual Meeting: proceedings 14–18

  18. Kakehi Y (2003) Watchful waiting as a treatment option for localized prostate cancer in the PSA era. Jpn J Clin Oncol 33:1–5

    Article  PubMed  Google Scholar 

  19. Lacronique V, Boureux A, Valle VD (1997) A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 278:1309–12

    Article  PubMed  CAS  Google Scholar 

  20. Alvarez JV, Greulich H, Sellers WR (2006) Signal transducer and activator of transcription 3 is required for the oncogenic effects of non–small-cell lung cancer–associated mutations of the epidermal growth factor receptor. Cancer Res 66:3162–8

    Article  PubMed  CAS  Google Scholar 

  21. Xiong H, Zhang ZG, Tian XQ (2008) Inhibition of JAK1, 2/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells. Neoplasia 10:287–97

    PubMed  CAS  Google Scholar 

  22. Ram PT, Horvath CM, Lyengar R (2000) Stat3-mediated transformation of NIH-3T3 cells by the constitutively active Q205L Gαo protein. Science 287:142–4

    Article  PubMed  CAS  Google Scholar 

  23. Tu Y, Zhong Y, Fu J. Activation of JAK/STAT signal pathway predicts poor prognosis of patients with gliomas. Med Oncol. In press

  24. Wang T, Niu G, Kortylewski M (2004) Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 10:48–54

    Article  PubMed  Google Scholar 

  25. Cozzi PJ, Wang J, Delprado W et al (2005) MUC1, MUC2, MUC4, MUC5AC and MUC6 expression in the progression of prostate cancer. Clin Exp Metastasis 22:565–73

    Article  PubMed  CAS  Google Scholar 

  26. Seitz C, Djavan B (2006) Biological markers of prostate cancer. Ann Urol (Paris) 40:329–35

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. China-America Cancer Research Institute of Guangdong Medical College, Dongguan, Guangdong, 523808, People’s Republic of China

    Xingyan Liu, Zhiwei He, Guoliang Huang & Congcong Ding

  2. Key Laboratory of Medical Molecular Activity Research, Dongguan, Guangdong, 523808, People’s Republic of China

    Cai-hong Li

  3. Guangdong Medical College, Dongguan, Guangdong, 523808, People’s Republic of China

    Hong Liu

Authors
  1. Xingyan Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zhiwei He
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cai-hong Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Guoliang Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Congcong Ding
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hong Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hong Liu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Liu, X., He, Z., Li, Ch. et al. Correlation Analysis of JAK-STAT Pathway Components on Prognosis of Patients with Prostate Cancer. Pathol. Oncol. Res. 18, 17–23 (2012). https://doi.org/10.1007/s12253-011-9410-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-011-9410-y

Keywords

Search

Navigation